Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $13,704,600 | $12,872,952 | $11,442,352 | $8,057,082 |
| - Cash | $233,000 | $251,100 | $262,900 | $340,800 |
| + Debt | $455,100 | $428,400 | $262,900 | $440,400 |
| Enterprise Value | $13,926,700 | $13,050,252 | $11,442,352 | $8,156,682 |
| Revenue | $2,355,300 | $1,887,100 | $1,488,700 | $1,133,500 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Gross Profit | $2,321,300 | $1,847,400 | $1,465,500 | $1,119,200 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| EBITDA | $639,700 | $416,100 | $264,600 | $138,100 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |
| Net Income | $341,300 | $249,700 | $154,500 | $89,600 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| % Growth | 33.2% | 58.3% | 69.6% | – |
| Operating Cash Flow | $595,400 | $389,900 | $339,400 | $256,500 |
| Capital Expenditures | -$38,200 | -$28,300 | -$16,500 | -$23,400 |
| Free Cash Flow | $557,200 | $361,600 | $322,900 | $233,100 |